AGN 193109 (sodium salt)

Confirm delete?

Zoom

Cat No: 23975

Biochemicals - Receptor Pharmacology

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd = 2, 2, and 3 nM for RARα, β, and γ, respectively).{41300} It is selective for RARs over retinoid X receptors (RXRs; Kd = >10,000 nM for human RXRα, β, and γ receptors). AGN 193109...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-benzoic acid, monosodium salt

Correlated keywords:

171746-21-7 AGN193109 CD 3106 ECE161 ECE 16-1 161

Product Overview:
AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd = 2, 2, and 3 nM for RARα, β, and γ, respectively).{41300} It is selective for RARs over retinoid X receptors (RXRs; Kd = >10,000 nM for human RXRα, β, and γ receptors). AGN 193109 reverses changes in cell morphology induced by the RAR agonist TTNPB (Item No. 16144) in ECE16-1 human endometrial ectocervical epithelial cells. It also reverses the growth suppressive effects of all-trans-RA, 13-cis-RA, and 9-cis-RA (Item No. 14587) when used at a 10-fold molar excess. AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.{41301}

Size	500 µg
Shipping	dry ice
Molecular Formula	C₂₈H₂₃O₂ • Na
SMILES	CC(C=C1)=CC=C1C2=CCC(C)(C)C3=C2C=C(C#CC4=CC=C(C([O-])=O)C=C4)C=C3.[Na+]
Molecular Weight	414,5
Formulation	A solid
Purity	≥98%
Custom Code	2916.39
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.